HC Wainwright Comments on Cibus' Q4 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS - Free Report) - Stock analysts at HC Wainwright reduced their Q4 2024 earnings per share estimates for Cibus in a research report issued on Monday, November 11th. HC Wainwright analyst A. Dayal now anticipates that the company will post earnings per share of ($1.00) for the quarter, down from their previous estimate of ($0.96). HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Cibus' current full-year earnings is ($3.50) per share. HC Wainwright also issued estimates for Cibus' FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($1.05) EPS.

Several other equities research analysts have also issued reports on CBUS. Canaccord Genuity Group upgraded shares of Cibus to a "strong-buy" rating in a report on Friday, July 19th. Alliance Global Partners decreased their price objective on shares of Cibus from $25.00 to $23.50 and set a "buy" rating for the company in a research note on Tuesday, September 24th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 target price on shares of Cibus in a research note on Tuesday, October 22nd.

Cibus Trading Down 7.7 %

Shares of NASDAQ CBUS traded down $0.41 during trading hours on Wednesday, hitting $4.90. 135,420 shares of the company traded hands, compared to its average volume of 137,519. The stock has a market capitalization of $129.65 million, a price-to-earnings ratio of -0.22 and a beta of 1.79. The company's 50 day moving average price is $4.05 and its 200 day moving average price is $8.60. Cibus has a 12 month low of $2.86 and a 12 month high of $23.18.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. FMR LLC increased its position in Cibus by 16.9% during the 3rd quarter. FMR LLC now owns 3,913,279 shares of the company's stock valued at $12,757,000 after purchasing an additional 566,328 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Cibus by 14.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company's stock valued at $161,000 after buying an additional 6,276 shares during the period. SG Americas Securities LLC bought a new position in Cibus in the third quarter worth approximately $33,000. Armistice Capital LLC purchased a new stake in Cibus during the second quarter worth $5,083,000. Finally, Squarepoint Ops LLC bought a new stake in Cibus during the 2nd quarter valued at $214,000. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.